Comparative clinical trial of Langenlianqiao oral liquid and Lianhuaqingwen capsule in the treatment of mild cases of coronavirus disease 2019 (COVID-19)
Compared with the placebo control group, the LGLQ group showed an improvement in the clinical symptoms of COVID-19 and a decrease in the duration of hospitalisation and infection, which confirmed that the LGLQ treatment had the same antiviral effect as the LHQW treatment. This may provide in-depth insights for antiviral therapy research.
Authors
- Yizhao Liu (ORCID: https://orcid.org/0000-0001-5477-8940)
- Mi Zhou (ORCID: https://orcid.org/0000-0002-0864-9512)
- Yanli Yang (ORCID: https://orcid.org/0000-0002-5847-7632)
- Qin-Xuan Li
Institutions
- Central South University (CN)
- The First People's Hospital of Changde (CN)
Publication Details
- Journal
- Journal of Health Population and Nutrition
- Published
- 2024-10-12
- DOI
- https://doi.org/10.1186/s41043-024-00649-6
- Citations
- 2
- Primary Topic
- Pharmacological Effects of Natural Compounds
- Type
- article
- Field-Weighted Citation Impact
- 0.93